SAT0276 Improvements in Productivity at Paid Work and Within Household, and Increased Participation in Daily Activities After 24 Weeks of Certolizumab Pegol in Patients with Psoriatic Arthritis: Results of Rapid-PSA Study

Abstract

BackgroundPsoriatic arthritis (PsA) is associated with severe work disability and loss of productivity.1 The efficacy and safety of certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, in PsA has been reported...